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Abstract
The discovery of insulin in 1921 changed the prognosis for people with type 1 diabetes. A century later, availability and
affordability of insulin remain a challenge in many parts of the globe. Using the WHO’s framework on understanding the life
cycle of medicines, this review details the global and national challenges that affect patients’ abilities to access and afford insulin.
Current research and development in diabetes has seen some innovations, but none of these have truly been game-changing.
Currently, three multinational companies control over 95% of global insulin supply. The inclusion of insulin on the WHO’s
Prequalification Programme is an opportunity to facilitate entry of new companies into the market. Many governments lack
policies on the selection, procurement, supply, pricing and reimbursement of insulin. Moreover, mark-ups in the supply chain
also affect the final price to the consumer. Whilst expenses related to diabetes are mostly covered by insurance in high-income
countries, many patients from low- and middle-income countries have to pay out of their own pockets. The organisation of
diabetes management within the healthcare system also affects patient access to insulin. The challenges affecting access to insulin
are complex and require a wide range of solutions. Given that 2021 marks the centenary of the discovery of insulin, there is need
for global advocacy to ensure that the benefits of insulin and innovations in diabetes care reach all individuals living with
diabetes.
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Introduction
The year 2021 marks a momentous milestone for the diabetes
community, with the centenary of the discovery of insulin.
Insulin’s discovery by Banting and Best at the University of
Toronto (ON, Canada) in 1921 meant that type 1 diabetes
went from being a death sentence to a manageable chronic
condition. Leonard Thompson was the first person to receive
insulin as a treatment for type 1 diabetes in 1922 in Canada.
That same year, Elliot Joslin stated, ‘A new race of diabetics
[people with diabetes] has come upon the scene’ [1] due to the
discovery of insulin. Later, in 1925, in his book ‘A diabetic
life’ [2], Robert D. Lawrence declared, ‘Now modern discov-
eries, particularly insulin, have completely changed the
outlook. There is no reason why a diabetic [person] should
not, if he can be taught to do so, lead a long normal life’.
However, these initial positive views on the prospects of
insulin therapy in the 1920s are in harsh contrast to the reality
that many people with diabetes face some 100 years later,
specifically owing to lack of access to insulin. Basu et al. [3]
found that, globally, in individuals with type 2 diabetes, one in
two people had access to the insulin they needed; whilst in sub-
Saharan Africa, this number was found to be to only one in
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seven people, highlighting the impact of poor health systems,
and lack of access to insulin and other tools necessary for
diabetes management, on the effective delivery of diabetes care.
Global barriers to insulin access
In 2016, the former Director-General of theWHO declared that
‘people with diabetes who depend on life-saving insulin pay the
ultimate price when access to affordable insulin is lacking’ [4].
A study in 13 low- and middle-income countries (LMICs),
published in 2019, found that mean availability of insulin was
55–80% in facilities that should have had insulin available on
the day of study [5]. Furthermore, in looking at standardised
prices per 10 ml vial of 100 U insulin in this study, the median
price governments pay (the government procurement price) for
human insulin was shown to be US$5, with analogue (long-
acting) insulin being 6.6 times more expensive. Across public
and private pharmacies and private hospitals, the median price
that an individual has to pay for human insulin is US$9 [5].
Clearly, in LMICs, these prices are out of reach for most indi-
viduals; however, the affordability of insulin is also an issue in
high-income countries [6–8]. The WHO’s framework on
understanding the life cycle of medicines [9] provides a useful
model for understanding the complexity of the barriers to access
to insulin that are present globally (Fig. 1).
Research and development and innovation The first compo-
nent of the WHO framework [9] is research and development
(R&D) and innovation. In a study in 2016, Kaplan and Beall
looked at insulin-related patents to assess R&D and innova-
tion and found that no patents existed for human insulin and
many patents for analogue insulins expired in 2015 for prod-
ucts already on the market [10]. Most of the patents were filed
by large multinational companies, with a few of the patents
identified being from companies in China and India. In the
USA, more than half of patents were found to be for insulin-
delivery devices rather than insulin itself [11].
The transition from animal to human and then analogue
insulin is seen as an innovation [12], but one that comes at a
higher price [13, 14]. Some innovations in modes of adminis-
tration of insulin (inhalable or oral insulin) have not shown
any success [15, 16]. The promising so-called ‘smart insulin’
or glucose-responsive insulin that would reduce the risk of
hypoglycaemia associated with insulin’s use is one innovation
that is currently in the pipeline [17].
Manufacturing In looking at the manufacturing of insulin, two
factors need to be considered: (1) insulin is a complex biolog-
ical product that requires specific expertise to manufacture in
order to ensure a high quality, safe and efficacious product [6];
(2) at present, the manufacturing of insulin is concentrated in
three large multinational companies—Eli Lilly, NovoNordisk
and Sanofi (known as ‘the big three’). Eli Lilly, Novo Nordisk
and Sanofi have a 96% share of the insulin market by volume
and hold 99% of the market by value [6]. Other insulin
manufacturing companies have been identified, including
producers in India and China [18], but their current impact
on the global market is negligible. In parallel to industrial
production, so-called ‘biohackers’ are attempting to provide
an open-source method for the production of insulin to possi-
bly lower the costs of production, as well as increase compe-
tition [19]. Gotham et al. [20] estimated that the cost of
production for human insulin for a 10 ml 100 U vial would
be between US$2.28 and US$3.42, whilst the cost of
manufacturing most formulations of analogue insulin was
slightly higher (US$3.69–6.34), with the exception of insulin
detemir, with costs of production of US$13.47–17.35. In
comparing the median government procurement prices in
different countries with the cost of production, procurement
prices were found to range from 1.8 to 2.6 times higher than
production costs for human insulin, and 2.0 to 9.3 times higher
than production costs for analogue insulin (Fig. 2).
Marketing and registrationAll medicines are required to have
marketing authorisation and must be registered by a national
regulatory agency before placement on the market. This
requires scientific evaluation of the product to ensure that it
meets specific standards of safety, efficacy and quality [21].









Fig. 1 Schematic of WHO framework on understanding the life cycle of
medicines [9]. This framework provides the key elements from a medi-
cine’s discovery until it is used by an individual, highlighting key barriers
along this pathway. This figure is available as part of a downloadable
slideset
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complex than for chemical entities. For biosimilars, generics
of biological products, the process of regulatory assessment is
demanding and includes the need for clinical trials [22]. These
requirements affect the cost of insulin and the entry of
biosimilar products into the market.
In parallel to the complex process that is needed for insulin
manufacturers to produce and get their products approved by
regulatory agencies, there is also the challenge that many
regulatory agencies in LMICs do not have the technical capac-
ity to assess the data in the dossiers prepared for biological
products. To address this, the WHO developed the
Prequalification Programme in 2001, mainly in response to
HIV/acquired immune deficiency syndrome (AIDS), to assess
the quality of anti-retroviral products. The WHO announced
the launch of prequalification for insulin in November 2019
[23]. This allows any producer of insulin to submit their prod-
uct for regulatory review by the WHO. Through this process,
competition in the insulin market will hopefully be increased
whilst ensuring safety and efficacy of products for govern-
ments and their populations.
Selection, pricing and reimbursement Just because a medicine
meets regulatory standards, this does not necessarily mean
that it is selected and used. The WHO’s Model Essential
Medicines List (EML) is aimed at guiding individual countries
with regard to their decisions on their choice of medicines, and
only includes guidance on soluble and intermediate-acting
insulin in vial form [24]. Although long-acting insulin
analogues were put forward for inclusion on this list in
2019, they were not included because the ‘available evidence
shows efficacy and safety advantages of analogues compared
to human insulin which are insufficiently large to justify the
cost differential that continues to exist.’ [25] For analogues to
be considered an essential medicine and included in the WHO
EML, more evidence is needed on their effectiveness, as well
as a decrease in their price [26].
For pricing of medicines, different countries have different
policy measures for both the system and individuals [27]. For
example, in Europe, these processes include health technology
assessments to help determine the ‘therapeutic value’ of a
medicine, referencing pricing, value-based pricing (price
established based on ‘added therapeutic value’), policies
encouraging the uptake of generic products and tendering at
different levels of the health system [28]. Such measures do
not exist in many LMICs [27] meaning that, as in the USA,

























Minimum           $2.28                 $2.24                 $2.16                 $1.67                $3.69                  $6.88                 $6.41                 $5.89
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Maximum          $3.42               $43.51               $36.70               $50.57              $17.35                $81.67             $124.90             $250.73
































Fig. 2 Costs of production and government procurement, and public and
private sector patient prices for human and analogue insulin, based on 43
countries. Data for cost of production from [20]; data for government
procurement costs and public and private sector patient prices from
[60]. This figure is available as part of a downloadable slideset
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increasing prices of insulin, as has been seen in the USA [29],
due to a lack of government control on medicine pricing.
Figure 2 shows the prices for government procurement of
insulin (per 10 ml vial of 100 U insulin), which range from
US$2.2 toUS$43.5 for human insulin andUS$6.9 to US$81.7
for analogue insulin.
In many LMICs, the price of insulin is paid for in full by an
individual [27] or, in some contexts, subsidies are in place
[30]. In contrast, in most high-income countries, a variety of
government-funded or insurance schemes provide some form
of financial protection, either ensuring that insulin is provided
for free to the individual or, at least, that the person does not
bear the full cost [27, 28].
Procurement and supply Pricing policies and approaches taken
by governments will affect howmedicines are procured. In most
LMICs, insulin is purchased via centralised tenders for the public
sector [31]. In the private sector, this is done via wholesalers and
private pharmacies. Another source of insulin includes donation
programmes, such as Life for a Child or Novo Nordisk’s
Changing Diabetes in Children [32]. Although these initiatives
have had a positive impact for individuals with type 1 diabetes,
they have not been integrated into the formal health system,
which raises issues of sustainability [32].
Once insulin is procured, dependent on the sector and
health system, the price difference between the government
procurement price and patient price might increase due to
import tariffs, storage costs, transportation costs, dispensing
fees, sales taxes and other fees. These mark-ups also apply at
different stages of the supply system in the private sector. Ball
et al. [33] found that these mark-ups cumulatively equalled
8.7–47.7% of the manufacturer’s selling price for locally
produced insulin and 10.0%–565.8% for imported insulins.
It is important to note that, beyond price, a variety of
geographical and health system factors can have an impact
on access to insulin, such as distance of the patient to
healthcare facilities [31].
Prescribing The prescribing of insulin is affected by the orga-
nisation of care and where in the health system (e.g. in the
hospital or in primary healthcare [PHC]) people can receive
their diabetes care. For example, in Vietnam, access to insulin
is mainly provided in major urban areas and in hospitals [34].
In some contexts, only specialists are able to prescribe insulin
[30]. At PHC level, there is often a lack of experience and
expertise, gaps in knowledge, fear of hypoglycaemia, missing
guidelines and even fear of prescribing insulin [35, 36].
Additional challenges to insulin prescribing include the fact
that some health professionals no longer know how to use
human insulin as they have received their training in contexts
where only analogue insulin is used [37] and the possible
impact that the pharmaceutical industry might have on
prescribing decisions of doctors [38, 39].
Dispensing Dispensing, or the provision of insulin by the
health system to an individual, faces two clear challenges in
many LMICs [30, 31, 34]: (1) the often-large distance
between communities and health facilities that provide diabe-
tes care; and (2) the fact that insulin prescriptions may only be
available from secondary or even tertiary healthcare facilities.
Beyond these factors, there is also the issue that the insulin
may not be available in the pharmacy when the individual
goes to get it. For example, in Peru, although insulin is
supposed to be available in the public sector, it is frequently
unavailable, resulting in people going to the private sector,
where insulin is more expensive [40]. Data from a variety of
countries show that median patient prices for human insulin in
the private sector are 2.2 times higher than in the public sector
(Fig. 2). In addition, in 13 countries in sub-Saharan Africa
[41–45], poor availability of insulin has been found in both
the public and private sectors (Fig. 3), as well as at different
levels of the health system, with, for example, insulin being
more highly available in hospitals than in PHC settings. The
WHO’s global action plan on noncommunicable diseases
(NCDs) [46] comprises a target of 80% availability of essen-
tial medicines, which includes insulin; of the 13 countries
studied in sub-Saharan Africa [41–45], only two met this
target in the public sector and one met it in the private sector
(Fig. 3).
Insulin use As noted by Holden et al. [47], in 1991, in the UK
most insulin was used by people with type 1 diabetes. The use
of insulin has increased globally, mainly due to the rising
prevalence of type 2 diabetes [8, 47], and will continue to do
so [3]. With this overall increase in use, a parallel increase in
the use of analogues has also been seen [6]. High insulin
prices mean that some people are not able to afford insulin
and, therefore, either forego or economise their insulin use by
not taking a full dose [6, 48]. Use of insulin is also influenced
by the patient’s socioeconomic status, poor knowledge of
diabetes, traditional beliefs, use of traditional medicine [35]
and misperception of insulin as a ‘last resort’ therapy [49].
Basu et al. [3] also highlight that overuse of insulin can have
a negative impact on disability-adjusted life years, especially
in older populations.
Beyond insulin
Since insulin needs to be injected, access to syringes or other
delivery devices are essential for insulin therapy and are often
not available and affordable [30]. Availability and affordabil-
ity of diagnostic tests in healthcare facilities and glucose
meters for self-monitoring of blood glucose was found to be
poor in many LMICs [30, 50]. Ogle et al. [51] looked at a
variety of LMICs and found that the annual median cost for
the management of diabetes (insulin, blood glucose meters,
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test strips, syringes and HbA1c tests) was US$533 (range:
US$255 in Pakistan to US$1185 in Burkina Faso). Beyond
these tools, a variety of health system factors are needed for
the management of diabetes and these are particularly lacking
in LMICs. The health system response for NCDs (including
diabetes) proposed by the WHO focuses on PHC [46] and
lacks a clear focus on access to medicines and health products
and overall integrated health system responses [52]. In addi-
tion, other barriers to diabetes care are present, such as lack of
healthcare worker training and shifting certain roles in diabe-
tes management from doctors to nurses and other healthcare
professionals, ill-adapted organisation of care, poor availabil-
ity of tailored patient education materials and approaches rele-
vant to the contexts and realities of people living in LMICs,
lack of an active role of national diabetes associations in shap-
ing diabetes care and policy, and lack of overall resources
allocated to diabetes [53]. These various factors that impair
diabetes care result in a low or decreased life-expectancy for
people with type 1 diabetes [42, 48] and a gap in access to
insulin for people with type 2 diabetes, which, in turn, can lead
to excess morbidity and mortality.
Summary
Access to insulin is truly a global challenge, with a wide range
of issues that impact on an individual’s capacity to find and
afford the insulin they need for their survival (Fig. 4). The fact
that the insulin market is concentrated by three multinational
companies affects the global market and has ramifications at a
country level [6] . True innovation is lacking with regard to
insulin and the delivery of diabetes care [14]. Regulatory
requirements for insulin need to be stringent enough to protect
the population from substandard medicines without being a
barrier to market entry. The inclusion of insulin on the WHO
Prequalification Programme [23] should be seen as a major
advance in improving access to insulin in LMICs by allowing
other insulin manufacturers entry into the market.
Insulin provides an interesting example of how evidence
has not been adequately used to guide clinical practice.
Despite analogue insulin not being included in the WHO
Model EML, its uptake has been substantial despite its higher
price [6, 14, 24]. This change in practice has an impact on the
cost of diabetes management for both the individual and the
health system. In addition, pricing policies andmark-ups with-
in the health system and supply chain affect the overall finan-
cial burden of diabetes management [6, 30, 33].
Beyond the actual access to insulin, a variety of health
system factors further hamper access to care; these include
diabetes care being provided at hospitals vs in PHC, lack of
knowledge and expertise of health professionals with regard
to insulin therapy, and availability and affordability of
diabetes-related supplies [30, 34, 40]. These health system
factors can also have an impact on the overall cost of diabetes
management, with individuals needing to pay for travel from
their home to a facility where insulin is present or only being
able to access this medicine in the private sector at higher
prices [5, 30, 34, 40]. Although donation programmes have
shown some success in demonstrating that, if access to insulin
is improved, type 1 diabetes does not need to be a death
sentence in LMICs, these programmes need to be better inte-
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Fig. 3 Availability of insulin in the public and private sectors in a variety of countries in sub-Saharan Africa. Availability was measured as insulin being
present in a facility (public or private) on the day of the study visit. Data derived from [41–45]. This figure is available as part of a downloadable slideset
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At a global level, the United Nations’ sustainable develop-
ment goals (SDGs) [54] include targets on NCDs, access to
medicines and universal health coverage (UHC), which
should guide the global response to diabetes [46]. For type 1
diabetes, many countries do not necessarily provide full
coverage for insulin and diabetes supplies within the context
of UHC [55]; should these be provided in a comprehensive
way, this could have an impact on mortality [56]. To date, the
R&D and innovation
Current barriers                      Element of the WHO model                 Possible solutions
Involve people with diabetes in 
co-creating innovations; innovation not 
only in new technologies and medicines, 
but also new delivery of care models
True innovation to change the 
management of diabetes is lacking 
Complexity of manufacturing insulin; 
domination of insulin market by three 
multinational companies
Biosimilar companies; ‘biohackers’
Complexity of regulatory process; lack 
of regulatory capacity in LMICs local regulatory authorities
Lack of government policies on 
selection, pricing and reimbursement
Selection of human vs analogue insulin; 
development of pricing regulations; 
inclusion of insulin and related supplies 
in UHC packages
Weaknesses in procurement and 
supply systems; mark-ups within the 
supply chain
Strengthen medicine supply chains; 
pooled procurement; regulate or 
eliminate mark-ups within the supply 
chain
Poor organisation of diabetes care; lack 
of industry on prescribers
Strengthen delivery of diabetes care; 
development of adapted training and 
guidelines 
Poor organisation of diabetes care; 
poor availability of insulin within the 
system
Strengthen delivery of diabetes care; 
develop innovative models of delivery of 
medicines; increase role of pharmacists
High price of insulin; increase in 
prescribing of higher priced analogue 
insulin
Strengthen delivery of diabetes care; 
training of health professionals; 










Fig. 4 Summary of barriers and solutions to overcome these to improve access to insulin. This figure is available as part of a downloadable slideset
959Diabetologia  (2021) 64:954–962
global response to diabetes has mainly focused on prevention
rather than diabetes care and access to medicines [57]. Both
globally and nationally, a lack of leadership, civil society
mobilisation and guiding institutions has meant that the issue
of access to insulin has not been comprehensively addressed
[7]. The launch of the Global Diabetes Compact by WHO in
November 2020 [58] is a positive step; however, the content
and approach of this initiative still needs to be defined.
All solutions for improving access to insulin (Fig. 4) need
to have people with diabetes playing a key role, both being
driven by people with diabetes and being designed with
people with diabetes in mind. They must also include innova-
tions that decrease global inequalities. Different players will
need to be involved, including the WHO, diabetes associa-
tions, academia and the private sector. International support
is needed to advance WHO prequalification, strengthen
national regulatory agencies, and improve processes
surrounding the selection, pricing, reimbursement, procure-
ment and supply of insulin. For these aspects, the WHO plays
a crucial role in supporting its member states. The WHO or
other organisations within the United Nations can also devel-
op a pooled procurement mechanism for insulin and diabetes
management-related supplies. In addition, global clinical and
scientific diabetes societies have a role in the development of
context-appropriate and conflict-of-interest-free guidelines
and training. National governments can develop comprehen-
sive policies on selection and pricing of products for diabetes
management, ensure insulin and other diabetes supplies are
included in UHC packages and remove or regulate mark-ups
within the supply chain. Overall, health systems and the way
in which diabetes care is delivered needs to be strengthened,
ensuring that it is centred on the needs of people with diabetes.
The private sector has a clear mandate, which is included in
the SDGs and can play a role in addressing the challenge of
access to insulin. Initiatives should focus on creating true part-
nerships with other players (as is the case in other areas of
health [59]) and addressing the issue of the price of insulin in a
sustainable way. As aforementioned, one area that needs to be
further strengthened at a national and global level is civil soci-
ety mobilisation. Although global and national diabetes orga-
nisations exist and provide training, guidelines and education,
so far, they have failed to materialise into a truly global move-
ment and ensure that the voice of people with diabetes is
heard. The centenary of insulin offers a policy window for
this to happen and shape the future of access to insulin and
diabetes care globally.
Supplementary Information The online version contains a slideset of the
figures for download, which is available at https://doi.org/10.1007/
s00125-020-05375-2.
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